Sein métastatique RH+
EMBER-3 (J2J-OX-JZLC)
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD